NEWS

July 3, 2019

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based B...

July 1, 2019

Bukwang’s successful launch of Neomed toothpaste on home-shopping marked its expansion on OTC business.

  • A functional...

June 28, 2019

  • BNO BIO has invested $1 million in Nucleix, an Israeli bio-venture

  • The first global investment by BNO BIO since...

June 26, 2019

- to be completed within 2 years

Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM...

December 17, 2018

- Fast speed of study progression, expecting results in January next year

MLR-1023’s phase 2b study is completed on Decem...

November 29, 2018

Bukwang announced that it has completed the clinical trials of MLR-1023, a new diabetic drug candidate. This is a phase...

October 22, 2018

Bukwang Pharmaceutical announces that the company’s application to conduct phase 2 clinical study for new CNS drug candi...

August 14, 2018

On August 14, 2018, the two companies signed a contract to transfer all rights of Rivoceranib held by Bukwang Pharmaceut...

August 7, 2018

- 400 patient enrollment in 61 sites (US & KR)

Bukwang Pharmaceutical Co., Ltd. announced completion of global Phase 2b s...

July 4, 2018

More than 360 patients dosed out of 400 patients in the US and Korea

MLR-1023, a new anti-diabetic drug from Bukwang Phar...

Please reload

Recent
Please reload

|    ​Korean    |

7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square